EcoDrugPlus

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSMAMG00000010441
Gene Symbol: MAP3K12
1 Cross references
185 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSMAMG00000024155
Gene Symbol: MAP3K12
2 Cross references
191 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSMAMG00000000542
Gene Symbol: SI:CH211-45C16.2
3 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 5

Ensembl ID : ENSMAMG00000001009
Gene Symbol: MAP3K5
2 Cross references
203 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSMAMG00000013963
Gene Symbol: MAP3K8
3 Cross references
200 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSMAMG00000000186
Gene Symbol: MAP3K9
3 Cross references
193 Possible Orthologues:

Monoglyceride Lipase

Ensembl ID : ENSMAMG00000016299
Gene Symbol: MGLL
3 Cross references
208 Possible Orthologues:

Motilin Receptor

Ensembl ID : ENSMAMG00000011877
Gene Symbol: MLNR
3 Cross references
174 Possible Orthologues:

Muscarinic Acetylcholine Receptor M2-Like

Ensembl ID : ENSMAMG00000007422
Gene Symbol: LOC113132995
2 Cross references
185 Possible Orthologues:

Natriuretic Peptide Receptor 2

Ensembl ID : ENSMAMG00000001802
Gene Symbol: NPR2
2 Cross references
185 Possible Orthologues:

Natriuretic Peptide Receptor 3

Ensembl ID : ENSMAMG00000017698
Gene Symbol: NPR3
2 Cross references
211 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 1-Like

Ensembl ID : ENSMAMG00000005533
Gene Symbol: LOC113138381
3 Cross references
201 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).